Εμφάνιση απλής εγγραφής

dc.creatorKotsiou O.S., Vavougios G.D., Papagiannis D., Matsiatsiou E., Avgeri D., Fradelos E.C., Siachpazidou D.I., Perlepe G., Miziou A., Kyritsis A., Gogou E., Kalampokas S., Kalantzis G., Kotsios V.S., Gourgoulianis K.I.en
dc.date.accessioned2023-01-31T08:44:57Z
dc.date.available2023-01-31T08:44:57Z
dc.date.issued2022
dc.identifier10.3390/ijerph19106110
dc.identifier.issn16617827
dc.identifier.urihttp://hdl.handle.net/11615/75236
dc.description.abstractBackground: Antibody seroprevalence in rural communities remains poorly investigated. We compared the SARS-CoV-2 seroprevalence in two Greek communities in June and July 2021 after the end of the Delta-driven pandemic wave that started in November 2020. One community was affected worse than the other. Methods: The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing. Results: We found a high rate of SARS-CoV-2 seropositivity in both communities, approaching 77.5%. In the area with a higher burden of COVID-19, Malesina, seropositivity was achieved with vaccine-acquired and naturally acquired immunity, whereas in the low-burden context of Domokos, the high rates of seropositivity were achieved mainly with vaccination. Previously infected individuals were less likely to be vaccinated than previously uninfected adults. The antibody titers were significantly higher in previously infected, vaccinated participants than in unvaccinated ones. In total, 4% and 10% of the unvaccinated population were diagnosed seropositive for the first time while not knowing about the previous infection. Age and gender did not impact antibody titers in high-or low-burden contexts. Conclusions: Before the Omicron pandemic wave, herd immunity was reached in different contexts in Greece. Higher antibody titers were measured in infected vaccinated individuals than in infected unvaccinated ones. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.en
dc.language.isoenen
dc.sourceInternational Journal of Environmental Research and Public Healthen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85131017274&doi=10.3390%2fijerph19106110&partnerID=40&md5=845bff5b0c7f224b3406894828120f22
dc.subjectSARS-CoV-2 vaccineen
dc.subjectvirus vaccineen
dc.subjectantibodyen
dc.subjectCOVID-19en
dc.subjectdisease spreaden
dc.subjectepidemicen
dc.subjectvaccinationen
dc.subjectadaptive immunityen
dc.subjectadulten
dc.subjectantibody productionen
dc.subjectantibody titeren
dc.subjectArticleen
dc.subjectcontrolled studyen
dc.subjectfemaleen
dc.subjectGreeceen
dc.subjectherd immunityen
dc.subjecthumanen
dc.subjectmaleen
dc.subjectmiddle ageden
dc.subjectnonhumanen
dc.subjectpandemicen
dc.subjectseroprevalenceen
dc.subjectSevere acute respiratory syndrome coronavirus 2en
dc.subjectvaccinationen
dc.subjectvirus loaden
dc.subjectepidemiologyen
dc.subjectpandemicen
dc.subjectseroepidemiologyen
dc.subjectGreeceen
dc.subjectAdulten
dc.subjectCOVID-19en
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectPandemicsen
dc.subjectSARS-CoV-2en
dc.subjectSeroepidemiologic Studiesen
dc.subjectViral Vaccinesen
dc.subjectMDPIen
dc.titleLessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Waveen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής